News Channels

23 May 2018 FDA Grants Breakthrough Therapy Designation for Tafamidis for the Treatment of Patients with Transthyretin Cardiomyopathy
23 May 2018 FDA Grants Breakthrough Therapy Designation to Lenti-D™ for the Treatment of Cerebral Adrenoleukodystrophy
23 May 2018 FDA Accepts Supplemental Biologics License Application (BLA) and Grants Priority Review for Prophylactic and Pediatric Use for Bio Products Laboratory's Coagadex® (Coagulation Factor X, Human) for Treatment of Hereditary Factor X Deficiency
23 May 2018 mAbxience and Amneal Enter Into an Agreement for Bevacizumab Biosimilar in the United States
23 May 2018 Clementia Reports Positive Phase 2 Part B Data Showing Treatment with Palovarotene Significantly Reduces New Bone Growth in Patients with FOP
23 May 2018 Spero Therapeutics Announces Positive Top-Line Data for Two Product Candidates from its Potentiator Platform
23 May 2018 Esperion Announces Third Pivotal Phase 3 Study of Bempedoic Acid Meets Primary Endpoint
23 May 2018 HETLIOZ® (tasimelteon) Effective in Treating Jet Lag during Transatlantic Travel
23 May 2018 TCR Engineered T-Cells are coming out of the shadow to the light
23 May 2018 Aerpio Announces Initiation of Dosing in a Phase 1a, Multiple-Ascending Dose Study of AKB-4924, a Hypoxia-Inducible Factor-1 Alpha Stabilizer in Development for Inflammatory Bowel Disease
23 May 2018 Rocket Pharmaceuticals Presents Updated Data from Phase 1/2 Gene Therapy Trial of RP-L102 in Patients with Fanconi Anemia at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
23 May 2018 Janssen Announces European Commission Approval of JULUCA®▼ (dolutegravir/rilpivirine), the First Two-Drug Regimen, Once-Daily, Single-Pill for the Treatment of HIV-1
23 May 2018 F-star Announces First Patient Dosed in Phase I Clinical Trial of FS118, a First-in-Class Immuno-oncology Bispecific Antibody
23 May 2018 Phase 3 Registration Trial for Non-Muscle Invasive Bladder Cancer Achieves 42% Complete Response Rate at Three Months in Carcinoma in Situ Patients
23 May 2018 Acceleron Announces Initiation of PULSAR Phase 2 Trial of Sotatercept in Pulmonary Arterial Hypertension
23 May 2018 PanOptica Doses First Patient with New Formulation of PAN-90806, a Novel, Topical Anti-VEGF Eye Drop, in Phase 1/2 Clinical Trial
23 May 2018 Pfizer Begins a Phase 1/2 Study to Evaluate Respiratory Syncytial Virus (RSV) Vaccine
23 May 2018 Cellectis: Approval of UCART123 Amendment in AML to Accelerate Clinical Development
23 May 2018 Prota/MCRI Completes Enrolment of Phase 2b Multicentre Clinical Trial of Probiotic Oral Immunotherapy for the Treatment of Peanut Allergy (PPOIT-003)
23 May 2018 Lava Therapeutics Raises EUR 16 Million to Advance Bispecific Gamma-Delta T Cell Engager Platform

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up